Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HIV-1 recombinant Ad5 vaccine
- Development stage
- Phase 1
- Lead developer
- Merck
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The HIV-1 recombinant Ad5 vaccine is a viral vector-based vaccine designed to prevent HIV-1 infection and control viral replication. It utilizes a replication-defective adenovirus type 5 (Ad5) vector to deliver genetic material encoding specific HIV-1 proteins, namely Gag, Pol, and Nef, from HIV-1 clade B strains. The vaccine aims to elicit cell-mediated immune responses, particularly T-cell immunity, against these HIV-1 antigens. Developed by Merck & Co., this vaccine was notably evaluated in the Step Study (HVTN 502) and Phambili (HVTN 503) clinical trials. However, these trials were terminated due to the vaccine's failure to prevent HIV acquisition and, in certain subgroups, an observed increase in the risk of HIV infection, particularly in uncircumcised men with pre-existing Ad5 immunity.
- Other names
- MRKAd5 HIV-1 gag/pol/nef vaccineadenovirus type 5 (Ad5) vector vaccineAd5-vectored HIV-1 vaccineAd-5-vectored HIV-1 vaccineAd 5-vectored HIV-1 vaccine
02
Targets
Human immunodeficiency virus type 1 reverse transcriptaseGag (HIV-1 Gag polyprotein)Nef (HIV-1 Nef)
Beyond the preview
Go deeper on HIV-1 recombinant Ad5 vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HIV-1 recombinant Ad5 vaccine.